AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27932522 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphala and Ela decoction (Group A)
Number of subjects: 60
Study 27932522 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine mouthwash (Group B)
Number of subjects: 60
Study 25099940 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal colposcopy examination
Number of subjects: 727
Study 24231653 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction group (performed a distracting tone‐detection task)
Number of subjects: 164
Study 24231653 — intervention group
Group type: COMPARATOR
Intervention: Control group (did not perform a distracting task)
Number of subjects: 164
Study 24231653 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction task engagement
Number of subjects: 164
Study 24231653 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction effectiveness
Number of subjects: 164
Study 24231653 — intervention group
Group type: EXPERIMENTAL
Intervention: Executive functioning and pain affect
Number of subjects: 164
Study 23064279 — intervention group
Group type: EXPERIMENTAL
Intervention: Encouragement condition (1-page letter and phone call reminder)
Number of subjects: 1347
Study 23064279 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no encouragement)
Number of subjects: 1347
Study 23064279 — intervention group
Group type: EXPERIMENTAL
Intervention: Encouragement condition
Number of subjects: 1347
Study 23064279 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 1347
Study 20521030 — intervention group
Group type: COMPARATOR
Intervention: Baclofen (60, 90 mg/day) for 16 days
Number of subjects: 21
Study 20521030 — intervention group
Group type: COMPARATOR
Intervention: Mirtazapine (30 mg/day) for 14 days
Number of subjects: 21
Study 18460109 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 110
Study 18460109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 16002558 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine (0.32 microg.kg(‐1).min(‐1) over 30 min)
Number of subjects: 18
Study 16002558 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (2.3 mg/min over 50 min)
Number of subjects: 18
Study 12560436 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive upper-body exercise program (8-week duration, resistance training plus aerobic exercise using a Monark Rehab Trainer arm ergometer)
Number of subjects: 14
Study 12560436 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive upper-body exercise program
Number of subjects: 14
Study 12560436 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 14
Study 10891899 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 0
Study 10891899 — intervention group
Group type: COMPARATOR
Intervention: Best medical therapy
Number of subjects: 0
Study 10891899 — intervention group
Group type: EXPERIMENTAL
Intervention: Low postrandomization MMSE score
Number of subjects: 0
Study 10891899 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke after randomization
Number of subjects: 0
Study 9294799 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified tension band (AO technique)
Number of subjects: 18
Study 9294799 — intervention group
Group type: COMPARATOR
Intervention: Two parallel 4.5‐millimeter interfragmentary lag screws
Number of subjects: 18
Study 9294799 — intervention group
Group type: EXPERIMENTAL
Intervention: Four‐millimeter cannulated lag screws with a tension band wired through the screws
Number of subjects: 18
Study 8320510 — intervention group
Group type: EXPERIMENTAL
Intervention: Grommet insertion with adenoidectomy
Number of subjects: 78
Study 8320510 — intervention group
Group type: COMPARATOR
Intervention: Grommet insertion without adenoidectomy
Number of subjects: 78
Study 8320510 — intervention group
Group type: COMPARATOR
Intervention: Adenoidectomy alone
Number of subjects: 78
Study 2951520 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic uterine nerve ablation
Number of subjects: 21
Study 29806296 — intervention group
Group type: EXPERIMENTAL
Intervention: Interrupted suture at exercise position (observation group)
Number of subjects: 84
Study 29806296 — intervention group
Group type: COMPARATOR
Intervention: Interrupted suture at flexion knee position (control group)
Number of subjects: 84
Study 29806296 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 84
Study 27450907 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based brief intervention with normative drinking feedback
Number of subjects: 734
Study 24937302 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Teaching Associate (CTA) model
Number of subjects: 60
Study 24937302 — intervention group
Group type: COMPARATOR
Intervention: Traditional training
Number of subjects: 60
Study 22543874 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotion of dietary guidelines by nurse practitioners
Number of subjects: 0
Study 20550224 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukotriene receptor antagonists (LTRAs)
Number of subjects: 326
Study 20550224 — intervention group
Group type: COMPARATOR
Intervention: Inhaled corticosteroids (ICS)
Number of subjects: 326
Study 18457822 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental 'Think Biology' program
Number of subjects: 0
Study 18457822 — intervention group
Group type: COMPARATOR
Intervention: Conventional cold/flu education program
Number of subjects: 0
Study 15673691 — intervention group
Group type: EXPERIMENTAL
Intervention: MCI-196 6 g/day
Number of subjects: 33
Study 15673691 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 12627359 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral valacyclovir, 2 g q.i.d.
Number of subjects: 168
Study 12627359 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ganciclovir, 5 mg/kg q12h for 1 week, then 6 mg/kg once daily for 5 days per week
Number of subjects: 168
Study 10573697 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric fluid smear
Number of subjects: 1003
Study 10573697 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic criteria for infection
Number of subjects: 1003
Study 10573697 — intervention group
Group type: EXPERIMENTAL
Intervention: Causative organisms
Number of subjects: 1003
Study 8917146 — intervention group
Group type: EXPERIMENTAL
Intervention: Two cards listing seven core health maintenance concerns
Number of subjects: 0
Study 8917146 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief session with a nurse to identify health risks and develop a plan
Number of subjects: 0
Study 7985452 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal Body Temperature (BBT) graph monitoring
Number of subjects: 73
Study 3534249 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG servo-assistance
Number of subjects: 60
Study 3534249 — intervention group
Group type: COMPARATOR
Intervention: Three images per second technique
Number of subjects: 60
Study 30102085 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-borne expander
Number of subjects: 40
Study 30102085 — intervention group
Group type: COMPARATOR
Intervention: Tooth-borne expander
Number of subjects: 40
Study 27492941 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (12 weeks of physical exercise and monthly psycho-educational consultations)
Number of subjects: 147
Study 27492941 — intervention group
Group type: COMPARATOR
Intervention: Usual care (without structured physical exercise or psycho-educational consultations)
Number of subjects: 147
Study 27492941 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation
Number of subjects: 147
Study 23635809 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse practitioner/community health worker (NP/CHW) care
Number of subjects: 525
Study 23635809 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 525
Study 23094777 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT-O
Number of subjects: 197
Study 23094777 — intervention group
Group type: COMPARATOR
Intervention: TVT-S H
Number of subjects: 197
Study 23094777 — intervention group
Group type: COMPARATOR
Intervention: TVT-S U
Number of subjects: 197
Study 20223578 — intervention group
Group type: EXPERIMENTAL
Intervention: Kneeling position
Number of subjects: 24
Study 20223578 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing on a taboret
Number of subjects: 24
Study 20223578 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing on the floor
Number of subjects: 24
Study 18678160 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood-letting puncture plus red-hot needle therapy
Number of subjects: 129
Study 18678160 — intervention group
Group type: COMPARATOR
Intervention: Routine acupuncture
Number of subjects: 129
Study 16450688 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 37.5 mg/APAP 325 mg (mean, 4.3 tablets)
Number of subjects: 305
Study 16450688 — intervention group
Group type: COMPARATOR
Intervention: Codeine 30 mg/APAP 300 mg (mean, 4.6 tablets)
Number of subjects: 305
Study 16450688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study 12891252 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF (filgrastim) 5 mg/kg/day
Number of subjects: 40
Study 12891252 — intervention group
Group type: COMPARATOR
Intervention: Control (0.9% NaCl)
Number of subjects: 40
Study 10367605 — intervention group
Group type: EXPERIMENTAL
Intervention: Low total cholesterol concentrations (<4.14 mmol/liter)
Number of subjects: 121
Study 10367605 — intervention group
Group type: COMPARATOR
Intervention: Total cholesterol
Number of subjects: 121
Study 10367605 — intervention group
Group type: COMPARATOR
Intervention: Triglycerides
Number of subjects: 121
Study 10367605 — intervention group
Group type: COMPARATOR
Intervention: Low-density lipoprotein cholesterol
Number of subjects: 121
Study 10367605 — intervention group
Group type: COMPARATOR
Intervention: Ratio of total cholesterol to high-density lipoprotein cholesterol
Number of subjects: 121
Study 8763372 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine
Number of subjects: 0
Study 8763372 — intervention group
Group type: EXPERIMENTAL
Intervention: Co‐phenylcaine forte
Number of subjects: 0
Study 1678735 — intervention group
Group type: EXPERIMENTAL
Intervention: Metadoxine 900 mg twice daily eluted in 500 ml of saline infusion
Number of subjects: 40
Study 1678735 — intervention group
Group type: COMPARATOR
Intervention: Control group: 500 ml of saline infusion twice daily with equivalent doses of pyridoxine (40 mg/die) every morning
Number of subjects: 40
Study 7138952 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG biofeedback training (suppression of 3‐ to 7‐Hz activity)
Number of subjects: 8
Study 7138952 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG biofeedback training (enhancement of 12‐ to 15‐Hz activity)
Number of subjects: 8
Study 7138952 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG biofeedback training (simultaneous suppression of 3‐ to 7‐Hz and enhancement of 11‐ to 19‐Hz activity)
Number of subjects: 8
Study 30758402 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodoform paste (iodoform + camphorated parachlorophenol + ointment comprising prednisolone acetate 5.0 mg and rifamycin 1.5 mg)
Number of subjects: 23
Study 30758402 — intervention group
Group type: COMPARATOR
Intervention: Calen®/ZO paste
Number of subjects: 23
Study 29046518 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone (0.05 mg/kg)
Number of subjects: 120
Study 27089522 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 793
Study 27089522 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 793
Study 24333062 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythrocytapheresis
Number of subjects: 62
Study 24333062 — intervention group
Group type: COMPARATOR
Intervention: Whole blood phlebotomy
Number of subjects: 62
Study 22311382 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (40 mg)
Number of subjects: 0
Study 22311382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19083205 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted surgery
Number of subjects: 87
Study 19083205 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 87
Study 17314582 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular injection of ultracain
Number of subjects: 19
Study 17314582 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection (saline)
Number of subjects: 19
Study 15366332 — intervention group
Group type: EXPERIMENTAL
Intervention: Lantigen B
Number of subjects: 212
Study 15366332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study 11196267 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) 5.0 microg/kg per day
Number of subjects: 123
Study 11196267 — intervention group
Group type: COMPARATOR
Intervention: Granulocyte colony-stimulating factor (G-CSF) 10.0 microg/kg per day
Number of subjects: 123
Study 11196267 — intervention group
Group type: EXPERIMENTAL
Intervention: ICE chemotherapy (ifosfamide, carboplatin, etoposide)
Number of subjects: 123
Study 9638315 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg pantoprazole daily
Number of subjects: 40
Study 9638315 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg ranitidine daily
Number of subjects: 40
Study 9638315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 8052927 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse methylprednisolone (400 mg/day)
Number of subjects: 102
Study 8052927 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisolone (50 mg/day)
Number of subjects: 102
Study 8052927 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse methylprednisolone
Number of subjects: 102
Study 8052927 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisolone
Number of subjects: 102
Study 2720577 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg MS Contin tablet
Number of subjects: 51
Study 2720577 — intervention group
Group type: COMPARATOR
Intervention: Three 30 mg MS Contin tablets
Number of subjects: 51
Study 2720577 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release morphine
Number of subjects: 51
Study 4417355 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammography and clinical examination (screening)
Number of subjects: 1000
Study 31154571 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-mg zinc gluconate for 12 weeks
Number of subjects: 60
Study 31154571 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 60
Study 31011823 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 1.5% eyedrops
Number of subjects: 169
Study 31011823 — intervention group
Group type: COMPARATOR
Intervention: Oral doxycycline
Number of subjects: 169
Study 28834897 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% xenon
Number of subjects: 160
Study 28834897 — intervention group
Group type: EXPERIMENTAL
Intervention: 75% xenon
Number of subjects: 160
Study 28834897 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% xenon
Number of subjects: 160
Study 28834897 — intervention group
Group type: COMPARATOR
Intervention: Control (50% nitrogen)
Number of subjects: 160
Study 25968598 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulforaphane (60 mg daily for 6 months)
Number of subjects: 78
Study 25968598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 25968598 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulforaphane
Number of subjects: 78
Study 22411260 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodentine
Number of subjects: 397
Study 22411260 — intervention group
Group type: COMPARATOR
Intervention: Z100®
Number of subjects: 397
Study 22411260 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodentine covered with Z100®
Number of subjects: 397
Study 22090487 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine 10 mg
Number of subjects: 17
Study 22090487 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine 20 mg
Number of subjects: 17
Study 22090487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 19085178 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-dermal fentanyl (TDF) patch (Group F, n=25)
Number of subjects: 50
Study 19085178 — intervention group
Group type: COMPARATOR
Intervention: Sustained-release oral morphine (SRM) (Group M, n=25)
Number of subjects: 50
Study 19085178 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-dermal fentanyl (TDF) patch (Group F)
Number of subjects: 50
Study 19085178 — intervention group
Group type: COMPARATOR
Intervention: Sustained-release oral morphine (SRM) (Group M)
Number of subjects: 50
Study 19085178 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (TDF and SRM)
Number of subjects: 50
Study 16529596 — intervention group
Group type: EXPERIMENTAL
Intervention: More frequent vital sign evaluation
Number of subjects: 0
Study 12893551 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer tutoring groups
Number of subjects: 0
Study 12893551 — intervention group
Group type: COMPARATOR
Intervention: Medical teacher groups
Number of subjects: 0
Study 11069570 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic-supplemented formulas (Bifidobacterium lactis Bb-12 or Lactobacillus strain GG)
Number of subjects: 27
Study 11069570 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic-supplemented formulas
Number of subjects: 27
Study 11069570 — intervention group
Group type: COMPARATOR
Intervention: Unsupplemented formula
Number of subjects: 27
Study 9176021 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 24
Study 9176021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 1485612 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 928
Study 3510539 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 21
Study 3510539 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 21
Study 31673048 — intervention group
Group type: EXPERIMENTAL
Intervention: miRNA profile assessment using small RNA sequencing
Number of subjects: 66
Study 31673048 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of miRNAs from the C14MC cluster
Number of subjects: 66
Study 31673048 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of confounders (age, BMI, time to centrifugation)
Number of subjects: 66
Study 29659193 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 27-mg chewable tablet
Number of subjects: 192
Study 29659193 — intervention group
Group type: COMPARATOR
Intervention: Orlistat 60-mg capsule
Number of subjects: 192
Study 29659193 — intervention group
Group type: COMPARATOR
Intervention: Orlistat 120-mg capsules (2 60-mg capsules)
Number of subjects: 192
Study 27054284 — intervention group
Group type: EXPERIMENTAL
Intervention: Earplugs
Number of subjects: 51
Study 27054284 — intervention group
Group type: COMPARATOR
Intervention: Unprotected group
Number of subjects: 51
Study 24073873 — intervention group
Group type: EXPERIMENTAL
Intervention: FOS (4 g × 2 times/d)
Number of subjects: 0
Study 24073873 — intervention group
Group type: COMPARATOR
Intervention: Control (sucrose group)
Number of subjects: 0
Study 22013924 — intervention group
Group type: EXPERIMENTAL
Intervention: UVB exposure once a week
Number of subjects: 60
Study 22013924 — intervention group
Group type: EXPERIMENTAL
Intervention: UVB exposure every second week
Number of subjects: 60
Study 22013924 — intervention group
Group type: EXPERIMENTAL
Intervention: UVB exposure once every fourth week
Number of subjects: 60
Study 22013924 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 19965647 — intervention group
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA) added to daunorubicin/Ara-C/thioguanine chemotherapy
Number of subjects: 1075
Study 19965647 — intervention group
Group type: COMPARATOR
Intervention: Daunorubicin/Ara-C/thioguanine chemotherapy without ATRA
Number of subjects: 1075
Study 19965647 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRA in patients with lower MN1 levels
Number of subjects: 1075
Study 19965647 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRA in patients with normal karyotype
Number of subjects: 1075
Study 17493066 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with latex extract
Number of subjects: 40
Study 17493066 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 16275834 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate model including T2 burden of disease
Number of subjects: 1328
Study 16275834 — intervention group
Group type: COMPARATOR
Intervention: Multivariate model without T2 burden of disease
Number of subjects: 1328
Study 14608241 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol administration
Number of subjects: 12
Study 14608241 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine administration
Number of subjects: 12
Study 10499752 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-over-the-needle group (Spinocath, 22-gauge)
Number of subjects: 20
Study 10499752 — intervention group
Group type: COMPARATOR
Intervention: Microcatheter-through-the-needle group (Portex, 28-gauge)
Number of subjects: 20
Study 10499752 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 8880369 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal gap condition
Number of subjects: 0
Study 8880369 — intervention group
Group type: COMPARATOR
Intervention: Control non-gap condition
Number of subjects: 0
Study 1534955 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal wall massage (20 min sessions, 9 sessions over 3 weeks)
Number of subjects: 16
Study 1534955 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal wall massage
Number of subjects: 16
Study 1534955 — intervention group
Group type: COMPARATOR
Intervention: Control phase (no massage)
Number of subjects: 16
Study 6403101 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg daily for one year (premenoausal)
Number of subjects: 1005
Study 6403101 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg daily for one year (postmenopausal)
Number of subjects: 1005
Study 6403101 — intervention group
Group type: COMPARATOR
Intervention: No systemic treatment (controls, postmenopausal)
Number of subjects: 1005